Lung Cancer
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Previously untreated patients and those who had received prior intracranial radiotherapy responded to selpercatinib treatment.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Treatment was well tolerated and also associated with delayed progression in previously treated patients with NSCLC and METAmp/Ex14Δ.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Dual treatment with ramucirumab and erlotinib produced similar results in patients with ex21 and ex19 mutations.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
This study reports on the ZENITH20-2 cohort of previously treated patients with advanced NSCLC and an HER2 exon 20 insertion mutation.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Savolitinib had promising antitumor activity in patients with METex14+ NSCLC and showed acceptable tolerability.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
First-line treatment with osimertinib in patients with EGFR-mutated is associated with longer overall survival compared with other drugs in its class.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Researchers presented updated 5-year progression-free survival and overall survival data from a clinical trial evaluating the efficacy and safety of alectinib versus crizotinib in previously untreated patients with ALK-positive NSCLC.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Treatment with combination apatinib and gefitinib is associated with improved progression-free survival compared with treatment with gefitinib alone in patients with NSCLC and EGFR mutations.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
A phase 1 clinical trial of the HER3-directed antibody–drug conjugate patritumab deruxtecan shows potential for treating patients with EGFR-mutated NSCLC.
2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021
Study results show no increase in progression-free survival with combination treatment of osimertinib and bevacizumab compared with osimertinib alone for patients with advanced lung adenocarcinoma and an EGFR T790M mutation.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512